Top Markets
Coin of the day
Devonian Health Group Inc. Devonian Health Group Inc.

Devonian Health Group Inc.

DVHGF
Rangering i aksjer #29820
Devonian Health Group Inc. specializes in the creation of botanical-based... Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Aksjekurs
$7.00
Sist synkronisert: 2026-08-17
Markedsverdi
$19.47M
Endring (1 dag)
0.00%
Endring (1 år)
-35.19%
Land
CA
Handel Devonian Health Group Inc. (DVHGF)

Kategori

Inntekter for Devonian Health Group Inc. (DVHGF)
Inntekter i 2026 TTM: 0
Ifølge Devonian Health Group Inc. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Devonian Health Group Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
- -
KR